Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.

MLA

Bunupuradah, Torsak, et al. “Safety and Efficacy of a Double-Boosted Protease Inhibitor Combination, Saquinavir and Lopinavir/Ritonavir, in Pretreated Children at 96 Weeks.” Antiviral Therapy, vol. 14, no. 2, 2009, pp. 241–48. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=19430099&authtype=sso&custid=ns315887.

APA

Bunupuradah, T., van der Lugt, J., Kosalaraksa, P., Engchanil, C., Boonrak, P., Puthanakit, T., Mengthaisong, T., Mahanontharit, A., Lumbiganon, P., Tompkins, E., Burger, D., Ruxrungtham, K., & Ananworanich, J. (2009). Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks. Antiviral Therapy, 14(2), 241–248.

Chicago

Bunupuradah, Torsak, Jasper van der Lugt, Pope Kosalaraksa, Chulapan Engchanil, Pitch Boonrak, Thanyawee Puthanakit, Tawan Mengthaisong, et al. 2009. “Safety and Efficacy of a Double-Boosted Protease Inhibitor Combination, Saquinavir and Lopinavir/Ritonavir, in Pretreated Children at 96 Weeks.” Antiviral Therapy 14 (2): 241–48. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=19430099&authtype=sso&custid=ns315887.